Geode Capital Management, LLC Inhibikase Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.45 - $0.78 $80 - $138	-178 Reduced 0.2%	89,048 $44,000
Q2 2022 Aug 12, 2022	BUY	$0.63 - $1.44 $3,160 - $7,224	5,017 Added 5.96%	89,226 $66,000
Q1 2022 May 13, 2022	BUY	$1.03 - $1.77 $5,233 - $8,993	5,081 Added 6.42%	84,209 $124,000
Q4 2021 Feb 11, 2022	BUY	$1.38 - $2.17 $73,547 - $115,650	53,295 Added 206.31%	79,128 $116,000
Q3 2021 Nov 12, 2021	BUY	$1.79 - $2.81 $46,241 - $72,590	25,833 New	25,833 $49,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $29.3M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.